Development of rGO encapsulated polymeric beads as drug delivery system for improved loading and controlled release of doxycycline drug

Antibacterial and Osteogenic Doxycycline Imprinted Bioglass Microspheres to Combat Bone Infection

Currently, postoperative infection is a significant challenge in bone and dental surgical procedures, demanding the exploration of innovative approaches due to the prevalence of antibiotic-resistant bacteria. This study aims to develop a strategy for controlled and smart antibiotic release while accelerating osteogenesis to expedite bone healing. In this regard, temperature-responsive doxycycline (DOX) imprinted bioglass microspheres (BGMs) were synthesized. Following the formation of chitosan-modified BGMs, poly N-isopropylacrylamide (pNIPAm) was used for surface imprinting of DOX. The temperature-responsive molecularly imprinted polymers (MIPs) exhibited pH and temperature dual-responsive adsorption and controlled-release properties for DOX. The temperature-responsive MIP was optimized by investigating the molar ratio of N,N'-methylene bis(acrylamide) (MBA, the cross-linker) to NIPAm. Our results demonstrated that the MIPs showed superior adsorption capacity (96.85 mg/g at 35 °C, pH = 7) than nonimprinted polymers (NIPs) and manifested a favorable selectivity toward DOX. The adsorption behavior of DOX on the MIPs fit well with the Langmuir model and the pseudo-second-order kinetic model. Drug release studies demonstrated a controlled release of DOX due to imprinted cavities, which were fitted with the Korsmeyer-Peppas kinetic model. DOX-imprinted BGMs also revealed comparable antibacterial effects against Staphylococcus aureus and Escherichia coli to the DOX (control). In addition, MIPs promoted viability and osteogenic differentiation of MG63 osteoblast-like cells. Overall, the findings demonstrate the significant potential of DOX-imprinted BGMs for use in bone defects. Nonetheless, further in vitro investigations and subsequent in vivo experiments are warranted to advance this research.

One-Pot Synthesis of Ruthenium-Based Nanocatalyst Using Reduced Graphene Oxide as Matrix for Electrochemical Synthesis of Ammonia

Conventional ammonia production consumes significant energy and causes enormous carbon dioxide (CO₂) emissions globally. To lower energy consumption and mitigate CO₂ emissions, a facile, environmentally friendly, and cost-effective one-pot method for the synthesis of a ruthenium-based nitrogen reduction nanocatalyst has been developed using reduced graphene oxide (rGO) as a matrix. The nanocatalyst synthesis was based on a single-step simultaneous reduction of RuCl₃ into ruthenium-based nanoparticles (Ru-based NPs) and graphene oxide (GO) into rGO using glucose as the reducing agent and stabilizer. The obtained ruthenium-based nanocatalyst with rGO as a matrix (Ru_nano-based/rGO) has shown much higher catalytic activity at lower temperatures and pressures for ammonia synthesis than conventional iron catalysts. The rGO worked as a promising promoter for the electrochemical synthesis of ammonia due to its excellent electrical and thermal conductivity. The developed Ru_nano-based/rGO nanocatalyst was characterized using transmission electron microscopy (TEM), high-resolution transmission electron microscopy (HRTEM), scanning electron microscopy (SEM), energy-dispersive spectroscopy (EDS), ultraviolet-visible (UV-vis) absorption spectroscopy, X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FT-IR), dynamic light scattering (DLS), inductively coupled plasma mass spectrometry (ICP-MS), and X-ray photoelectron spectroscopy (XPS). The results demonstrated that the size of the Ru-based NPs on the surface of rGO was 1.9 ± 0.2 nm and the ruthenium content was 25.03 wt %. Bulk electrolysis measurements were conducted on thin-layer electrodes at various cathodic potentials in a N₂-saturated 0.1 M H₂SO₄ electrolyte at room temperature. From the chronoamperometric measurements, the maximum faradic efficiency (F.E.) of 2.1% for ammonia production on the nanostructured Ru_nano-based/rGO electrocatalyst was achieved at a potential of -0.20 V vs reversible hydrogen electrode (RHE). This electrocatalyst has attained a superior ammonia production rate of 9.14 μg·h^-1·mg_cat.^-1. The results demonstrate the feasibility of reducing N₂ into ammonia under ambient conditions and warrant further exploration of the nanostructured Ru_nano-based/rGO for electrochemical ammonia synthesis.

Potential Biomedical Limitations of Graphene Nanomaterials

Graphene-family nanomaterials (GFNs) possess mechanical stiffness, optical properties, and biocompatibility making them promising materials for biomedical applications. However, to realize the potential of graphene in biomedicine, it must overcome several challenges that arise when it enters the body's circulatory system. Current research focuses on the development of tumor-targeting devices using graphene, but GFNs accumulated in different tissues and cells through different pathways, which can cause toxic reactions leading to cell apoptosis and body dysfunction when the accumulated amount exceeds a certain limit. In addition, as a foreign substance, graphene can induce complex inflammatory reactions with immune cells and inflammatory factors, potentially enhancing or impairing the body's immune function. This review discusses the biomedical applications of graphene, the effects of graphene materials on human immune function, and the biotoxicity of graphene materials.

Reduced graphene oxide: Biofabrication and environmental applications

Green synthesis of high-quality reduced graphene oxide (rGO) from agro-industrial waste resources remains attractive owing to its outstanding environmental benefits. The remarkable properties of rGO include excellent morphology, uniform particle size, good optical properties, high conductivity, nontoxicity, and extraordinary chemical stability. Traditional methods for the synthesis of rGO nanomaterials involve several chemical reactions including oxidation, carbonization, toxic solvent, and pyrolysis which produce harmful byproducts. Green preparation of rGO is an emerging area of research in graphene technology which is cost-effective and sustainable in the procedure. Owing to the uniform particle rGO particle size, these smart nanomaterials have wide applicability, including in metal ions and pollutant sensing and adsorption, photocatalysis, optoelectrical devices, medical diagnosis, and drug delivery. Here we review the physicochemical properties of rGO, the biowaste sources and green methods of rGO synthesis, and the diverse applications of rGO, including in water purification and the biomedical fields. With this review, covering more than 200 research articles published on rGO in the last eight years ending in 2022, we aim to provide a quick guide for researchers seeking up-to-date information on the properties, production, and applicability of rGO, with special attention to rGO applications in water purification and the biomedical fields.

The Preliminary Study on the Proapoptotic Effect of Reduced Graphene Oxide in Breast Cancer Cell Lines

Breast cancer is the most common cancer diagnosed in women, however traditional therapies have several side effects. This has led to an urgent need to explore novel drug approaches to treatment strategies such as graphene-based nanomaterials such as reduced graphene oxide (rGO). It was noticed as a potential drug due to its target selectivity, easy functionalisation, chemisensitisation, and high drug-loading capacity. rGO is widely used in many fields, including biological and biomedical, due to its unique physicochemical properties. However, the possible mechanisms of rGO toxicity remain unclear. In this paper, we present findings on the cytotoxic and antiproliferative effects of rGO and its ability to induce oxidative stress and apoptosis of breast cancer cell lines. We indicate that rGO induced time- and dose-dependent cytotoxicity in MDA-MB-231 and ZR-75-1 cell lines, but not in T-47D, MCF-7, Hs 578T cell lines. In rGO-treated MDA-MB-231 and ZR-75-1 cell lines, we noticed increased induction of apoptosis and necrosis. In addition, rGO has been found to cause oxidative stress, reduce proliferation, and induce structural changes in breast cancer cells. Taken together, these studies provide new insight into the mechanism of oxidative stress and apoptosis in breast cancer cells.

Antibacterial calcium phosphate cement with human periodontal ligament stem cell-microbeads to enhance bone regeneration and combat infection

Infectious bone defects remain a significant challenge in orthopedics and dentistry. Calcium phosphate cement (CPC) have attracted significant interest in use as local drug delivery system, which with great potential to control release of antibiotics for the treatment of infectious bone defects. Within the current study, a novel antibacterial scaffold of chitosan-reinforced calcium phosphate cement delivering doxycycline hyclate (CPCC + DOX) was developed. Furthermore, the capacity of CPCC + DOX scaffolds for bone regeneration was enhanced by the human periodontal ligament stem cells (hPDLSCs) encapsulated in alginate beads. CPCC + DOX scaffolds were fabricated to contain different concentrations of DOX. Flexural strength of CPCC + DOX ranged from 5.56 ± 0.70 to 6.2 ± 0.72 MPa, which exceeded the reported strength of cancellous bone. Scaffolds exhibited continual DOX release, reaching 80% at 21 days. Scaffold with 5 mg/ml DOX (CPCC + DOX5mg) had a strong antibacterial effect, with a 4-log colony forming unit reduction against S. aureus and P. gingivalis. The proliferation and osteogenic differentiation of hPDLSCs encapsulated in alginate hydrogel microbeads were investigated in culture with CPCC + DOX scaffolds. CPCC + DOX5mg had no negative effect on proliferation of hPDLSCs. Alkaline phosphatase activity, mineral synthesis, and osteogenic gene expressions for CPCC + DOX5mg group were much higher than control group. DOX did not compromise the osteogenic induction. In summary, the novel CPCC + DOX scaffold exhibited excellent mechanical properties and strong antibacterial activity, while supporting the proliferation and osteogenic differentiation of hPDLSCs. The CPCC + DOX + hPDLSCs construct is promising to enhance bone regeneration and combat bone infections in dental, craniofacial, and orthopedic applications.

Injectable In-Situ Forming Depot of Doxycycline Hyclate/α-Cyclodextrin Complex Using PLGA for Periodontitis Treatment: Preparation, Characterization, and In-Vitro Evaluation

BACKGROUND

Doxycycline (DOX) is used in treating a bacterial infection, especially for periodontitis treatment.

OBJECTIVE

To reduce irritation of DOX for subgingival administration and increase the chemical stability and against enzymatic, the complex of α-cyclodextrin with DOX was prepared and loaded into injectable in situ forming implant based on PLGA.

METHODS

FTIR, molecular docking studies, X-ray diffraction, and differential scanning calorimetry was performed to characterize the DOX/α-cyclodextrin complex. Finally, the in-vitro drug release and modeling, morphological properties, and cellular cytotoxic effects were also evaluated.

RESULTS

The stability of DOX was improved with complex than pure DOX. The main advantage of the complex is the almost complete release (96.31 ± 2.56 %) of the drug within 14 days of the implant, whereas in the formulation containing the pure DOX and the physical mixture the DOX with α-cyclodextrin release is reached to 70.18 ± 3.61 % and 77.03 ± 3.56 %, respectively. This trend is due to elevate of DOX stability in the DOX/ α-cyclodextrin complex form within PLGA implant that confirmed by the results of stability.

CONCLUSION

Our results were indicative that the formulation containing DOX/α-cyclodextrin complex was biocompatible and sustained-release with minimum initial burst release.

Fabrication of chlorambucil loaded graphene- oxide nanocarrier and its application for improved antitumor activity

The present study aims at designing a biodegradable and biocompatible nanocarrier using gelatin and reduced graphene oxide nanosheets functionalized with folic acid, for release of chlorambucil drug in controlled manner and achieving high loading efficiency. From scanning electron microscopic studies small pore like structure with rough and thick morphology on the plane of graphene oxide is clearly visible indicating high loading of drug. Further, Drug loading and encapsulation efficiency, in vitro release studies of the drug from the nanocarrier at different concentrations of reduced graphene oxide, different pH were studied. The mean particle size, entrapment efficiency (%) of optimized folic acid functionalized gelatin-graphene oxide formulation was observed to be 300 nm and 56% respectively. From the release studies it is clear that, after 24 h the release rate of the drug was found to be higher at acidic conditions compared to neutral conditions. It was found that 62.1% and 82% of the total bound drug was released from the nanocarrier at pH 5.4 and pH 1.2 respectively. Besides, under neutral conditions (pH 7.4), 43.7% of the total bound drug was released from the nanocarrier in the first 24 h. The % cell viability of free drug, drug loaded nanocomposites against human cervical adenocarcinoma cell line was found to be 11.7% and 28% respectively at the dose of 500 μg mL^-1 after 24 h. IC50 values also manifest the significantly lower cytotoxicity of drug loaded nanocarrier (IC50 = 125.9 μg/mL) as compared to free-drug (IC50 = 86 μg/mL). For FAGGO, CLB and CLB-FAGGO the values of mean ± std. deviation were found to be 71.80 ± 6.66; 48.71 ± 23.15; 55.48 ± 19.65 respectively. The unique properties exhibited by biodegradable polymer like gelatin and carbon based materials such as graphene offers an excellent applications in biomedical field.